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Abstract
Background: Chronic-active antibody mediated rejection (c-aABMR) is a major contributor to long-term kidney
allograft loss. We conducted a retrospective analysis to establish the efficacy of treatment with intravenous
immunoglobulins (IVIG) and pulse methylprednisolone (MP) of patients with c-aABMR.
Methods: Sixty-nine patients, in the period 2005–2017, with the diagnosis (suspicious for) c-aABMR that were
treated with IVIG and MP were included. Patients were administered three doses of 1 g intravenous MP combined
with a single dose of IVIG (1 g/kg body weight). Primary outcome was the decline in allograft function one year
post treatment. Responders to IVIG-MP therapy were defined by an eGFR one year after treatment which was at
least 25% above the projected allograft function.
Results: Patients showed an average decline in eGFR of 9.8 ml/min/1.73m2 the year prior to treatment. Following
treatment, a significant reduction (p < 0.001) in eGFR decline was observed (6.3 ml/min/1.73m2). Furthermore, a
significant improvement in proteinuria was observed upon treatment (p < 0.001). Sixty-two percent (n = 43) of the
patients were considered a responder and showed considerable slowing of graft function deterioration in the year
after treatment (p < 0.001). Three and 5-year graft survival was significantly superior in responders.
Conclusions: More than 60% of patients with c-aABMR with a progressive decline in eGFR respond favorably to
treatment with IVIG-MP resulting in a significant improvement of graft survival (Sablik, Am J Transplant 18, 2018).
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Background
Short-term outcome of kidney transplants has improved
significantly due to the introduction of calcineurin inhibi-
tors (CNI), induction therapy with T cell depleting agents
and IL-2 receptor blocker [1–3]. However, improvement in
long-term renal allograft survival still presents a consider-
able clinical problem [4–7]. In recent years, chronic-active
antibody mediated rejection (c-aABMR) has become
recognized as one of the major barriers for long term renal
allograft survival [7–9].
Advanced c-aABMR often presents itself as a progres-
sive loss of allograft function, in addition to progressive
proteinuria and hypertension. Renal allograft survival is
poor as most patients develop allograft failure within 2
years after being diagnosed with c-aABMR [7, 10–13]. It
is therefore important to find therapeutic options for
c-aABMR that are aimed at stabilizing or slowing the
decrease in allograft function.
Currently, only little is published about the efficacy of
treatment after c-aABMR has been diagnosed. A number
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of studies have indicated that the use of rituximab (RTX),
tocilizumab, bortezomib, intravenous immunoglobulins
(IVIG) therapy and/or plasmapheresis (PP), may favorably
attenuate the loss of allograft function in patients with
chronic ABMR with or without transplant glomerulopathy
(TG) [14–19]. However, these studies were uncontrolled
and conducted with small numbers of patients over
relatively short periods of time. The recently published,
first and only randomized, placebo-controlled trial in late
ABMR (BORTEJECT), showed disappointing results upon
treatment with bortezomib as no improvement in eGFR
loss was achieved [20].
Our renal transplant center has, in the last decade,
adopted the policy to treat patients with c-aABMR with
a single course of IVIG and pulse intravenous MP based
on favorable initial results. In this study we retrospectively




We retrospectively identified renal transplant recipients
with biopsy proven (suspicious for) c-aABMR at the Eras-
mus Medical Center between January 2005 and January
2017. Patients were identified from the pathology database
at our center. A total of 167 patients were found eligible for
inclusion (Fig. 1). Patients with c-aABMR diagnosed at least
one year after transplantation were eligible for evaluation of
the effect of IVIG-MP treatment on the progressive de-
crease in graft function. The inclusion criteria were treat-
ment with three doses of 1 g intravenous MP over a 3 day
period combined with a single dose of IVIG (1 g/kg body
weight) and sufficient data (see below) on allograft function
for analysis and if no additional treatment was given (e.g.
Alemtuzumab, Anti-thymocyte globulin). Sixty-nine
patients were found eligible and were included as
cases. Additionally, a historical patient group (n = 27)
was identified that did not receive any additional
treatment upon c-aABMR diagnosis. Most of these
patients were diagnosed with c-aABMR before adapta-
tion of the local treatment guideline for c-aABMR in
2008.
All renal biopsies were for cause and evaluated at time
of biopsy by an experienced renal pathologist based on
the then current Banff classification [21–25]. Alternative
diagnoses for the histomorphological changes compatible
with c-aABMR such as membranoproliferative glomerulo-
nephritis (MPGN) or (chronic) thrombotic microangiopa-
thy (cTMA) were excluded, either by immunofluorescence
or clinical analysis.
Fig. 1 Patient selection flow chart
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This retrospective study was reviewed and approved by
the Institutional Ethics Committee from the Erasmus MC,
Rotterdam, The Netherlands. As this was a retrospective
study, written consent to participate from the study
subjects was not required.
Data collection
Demographic and baseline transplantation characteristics
were collected for all patients, as well as data on renal
allograft function and proteinuria. Renal allograft function
was assessed on the basis of estimated glomerular filtra-
tion rate (eGFR) by means of modification of diet in renal
disease (MDRD) [26]. All eGFR measurements sampled
during outpatient clinic visits in the year prior to and year
post diagnosis and/or treatment with IVIG-MP were in-
cluded. Measurements taken during hospitalization were
omitted from analysis to minimize bias due to, for ex-
ample, the admission of intravenous fluids, infection, etc.
Patients needed at least 7 measurements of eGFR at regu-
lar intervals in the year before and after treatment with
IVIG-MP. This was considered the minimal number of
data to perform multilevel statistical analysis (see below).
Allograft failure was defined as the need for dialysis or
kidney re-transplantation.
Similarly, data on proteinuria was collected also with a
minimum of 7 measurements at regular intervals in the
year before and after treatment with IVIG-MP.
Statistical analysis
Normally distributed data are expressed as mean +/− SD,
non-normally distributed data as median (IQR/range). A
P-value of less than 0.05 was considered statistically sig-
nificant. All statistical analysis were performed using the R
statistical programming environment and SPSS software
version 21.
The primary outcome of this study was the efficacy of
IVIG-MP therapy on allograft function in the first year
after treatment. This was analyzed by 2 different strat-
egies. First, the treatment efficacy was explored by
means of multilevel analysis. This model allows for the
detection of a change in allograft function based on the
statistical analysis of longitudinal data with intercept,
slope and number of observations varying across all pa-
tients. It is considered a successful method for providing
a reliable estimate of change in allograft function over
time [27]. This type of analysis shows the statistical sig-
nificance of the impact of IVIG-MP treatment for the
whole group of patients.
Secondly, all cases were classified as either responder or
non-responder. In order to stratify patients we determined
the slope of allograft deterioration for each individual pa-
tient. Based on their slope 1 year prior to diagnosis, a pro-
jection was made for their predicted graft function one
year after diagnosis. Patients with a measured eGFR at
one year after treatment of at least 25% above the projected
eGFR were classified as responder. To verify whether this
stratification is warranted, additional multilevel analysis was
performed for the responders as a group and the non-re-
sponders as a group. Graft survival censored for death after
IVIG-MP treatment was calculated using Kaplan-Meier
curves and log rank statistics. The efficacy of the IVIG-MP
treatment on proteinuria was analyzed similarly. The clin-
ical and demographical characteristics of responders and
non-responders were compared using unpaired t test for
continuous variables, Mann Whitney U test for ordinal var-




The demographic and clinical characteristics for the 69
cases at time of for-cause biopsy are summarized in
Table 1 (Additional file 1: Table S1, data on historic con-
trols). On average patients were 53 years old and a major-
ity was transplanted with a living donor kidney (75%). The
maintenance immunosuppressive regimen predominantly
consisted of double immunosuppression with a combin-
ation of tacrolimus and mycophenolate mofetil. Steroids
were used in less than half of the patients (46%).
Time to biopsy from the moment of transplantation
showed a median of 6.3 years (2.8–9.2 years). Patients
had a median eGFR of 34 mL/min/1.73m2 and 230mg/
mmol proteinuria at time of renal biopsy. No deaths oc-
curred within the first year of follow-up.
Renal allograft function and response to IVIG-MP
treatment
Renal allograft function of the 69 patients treated with
IVIG-MP declined from an average eGFR of 44ml/min/
1.73m2 at 1 year prior to therapy to 34ml/min/1.73m2 at
time of treatment (t0, IVIG-MP treatment). The year after
treatment, allograft function further declined to 28ml/
min/1.73m2. The course of eGFR is illustrated in Fig. 2a.
The calculated average decline in eGFR of 6.3 (5.3–7.3)
ml/min/1.73m2 in the year after IVIG-MP treatment was
significantly less than the average decline of 9.8 (8.9–10.8)
ml/min/1.73m2 in the year prior to treatment (multilevel
analysis, p < 0.001).
Sixty-two percent of patients (n = 43) had an eGFR one
year after treatment of at least 25% above the projected
eGFR and were categorized as responders. Figure 3 shows
typical examples of a non-responder (Fig. 3a), a responder
showing a significant slowing of progressive eGFR loss
(Fig. 3b) and a responder with a stabilization of renal func-
tion after treatment (Fig. 3c). The latter 2 patterns of re-
sponse were most frequent as improvement of eGFR
within the year after treatment was usually not observed.
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As a group, the responders had a decline in allograft
function from an eGFR of 43ml/min/1.73m2 1 year prior
to treatment to 33ml/min/1.73m2 at time of treatment
(decline in eGFR; 10.3 (9.2–11.5) ml/min/1.73m2). The
calculated average decline in eGFR after IVIG-MP treat-
ment was 2.0 (0.9–3.4) ml/min/1.73m2 (Fig. 2b). The
non-responders (n = 26) showed an average decline in
eGFR from 45ml/min/1.73m2 1 year prior to treatment to
36ml/min/1.73m2 at time of treatment (decline in eGFR;
9.1 (7.6–10.6) ml/min/1.73m2) which was similar to the
group of responders. The allograft function in the year
prior to treatment did not differ between responders
and non-responders (p = 0.19). In non-responders eGFR
declined to 24 ml/min/1.73m2 1 year after treatment
(Fig. 2c; decline in eGFR 12.0 (10.6–13.5) ml/min/
1.73m2).
Similar to the treated patients, eGFR loss was calculated
in the untreated historic patient group (n = 27) before and
after the diagnosis. The average decline in eGFR was 11.3
(9.5–13.0) ml/min/1.73m2 and 9.7 (7.9–11.6) ml/min/
1.73m2 respectively, with no significant change in graft
function (p = 0.33). These values are in range with the
decline in eGFR prior to diagnosis in patients treated with
IVIG-MP and in accordance with the unfavorable progno-
sis of c-aABMR as described in literature [12].
Renal allograft survival after IVIG-MP treatment
Three patients (non-responders) out of the 69 treated
patients showed relentless progression of disease to graft
failure and returned to dialysis within the first year after
IVIG-MP administration. The graft survival censored for
death after c-aABMR diagnosis for the responders and
Table 1 Clinical and demographic characteristics (record at time of c-aABMR diagnosis)
Total (n = 69) Responders (n = 43) Non-Responders (n = 26) p-value
Women, n (%) 25 (36) 14 (48) 11 (42) 0.41
Age of patient, yr, median (IQR) 53 (42–66) 54 (42–66) 52 (42–62) 0.40
Living donor, n (%) 52 (75) 35 (81) 17 (65) 0.14
Prior kidney transplant, n (%) 17 (25) 10 (23) 7 (27) 0.73
Donor age, yr, median (IQR) 50 (41–57) 53 (43–61) 47 (40–52) 0.05
PRA current, median (IQR) 0 (0–4) 0 (0–4) 0 (0–5) 0.79
HLA mismatch, median (IQR) 3 (2–4) 3 (2–4) 3 (3–4) 0.24
Maintenance immunosuppression, n (%) >0.05
❖ Tacrolimus/cyclosporine 57 (83) 37 (86) 20 (77)
❖ mTOR inhibitor 6 (9) 3 (7) 3 (12)
❖ Steroids 32 (46) 22 (51) 10 (38)
❖ Mycophenolate mofetil 59 (86) 37 (86) 22 (85)
❖ Other 2 (3) 0 (0) 2 (8)
Maintenance immunosuppression, n (%) 0.58
❖ Triple immunosuppression 21 (30) 15 (35) 6 (23)
❖ Double immunosuppression 44 (64) 25 (58) 19 (73)
❖ Single immunosuppression 4 (6) 3 (7) 1 (4)
Primary kidney disease, n (%) 0.65
❖ Diabetic nephropathy 7 (10) 5 (12) 2 (7)
❖ Hypertensive nephropathy 9 (13) 5 (12) 4 (15)
❖ Polycystic kidney disease 8 (12) 4 (9) 4 (15)
❖ Primary glomerulopathy 19 (28) 12 (28) 7 (27)
❖ Reflux nephropathy 5 (7) 2 (5) 3 (12)
❖ Chronic pyelonephritis 3 (4) 1 (2) 2 (7)
❖ Other 15 (22) 12 (28) 3 (12)
❖ Unknown 3 (4) 2 (5) 1 (4)
Time to c-aABMR, yr, median (IQR) 6.3 (2.8–9.2) 6.1 (2.7–8.9) 6.5 (3.6–10.5) 0.32
eGFR (ml/min/1.73m2), mean (SD) 34 (±2.0) 33 (±2.5) 36 (±3.4) 0.15
eGFR measurements, n, median (IQR) 19 (14–24) 18 (13–22) 19 (15–26) 0.51
Proteinuria (mg/mmol), mean (SD) 230 (157–302) 219 (108–329) 250 (178–323) 0.69
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non-responders is shown in Fig. 4. The responders had a
significantly improved graft survival with a mean sur-
vival of 5.9 (4.5–7.2) year versus 3.1 (2.4–3.8) year for
the non-responders (p = 0.003). Graft survival was simi-
lar for non-responders and the historic untreated patient
group (p = 0.94).
Graft survival after c-aABMR diagnosis at 1, 3 and 5
years was 100, 75 and 59%, respectively in the group of re-
sponders versus 89, 57 and 20% for the non-responders.
The group of untreated patients had similar survival to
the non-responders with 74, 38 and 33%, respectively.
Difference between responders and non-responders in
relation to clinical variables
Of all clinical variables, only age of the donor was found to
be significantly different between responders and non-re-
sponders (Table 1). On average responders had a slightly
older donor than non-responders (53 vs. 47 years; p =
0.046). However, responders more often received a kidney
from a living donor although this was not statistically
significant (81% vs. 65%, p = 0.14). There was no difference
in HLA mismatch nor whether the patient has received a
previous kidney transplant.
Renal allograft function at time of c-aABMR diagnosis
was similar as was proteinuria between the 2 patient
groups (p = 0.15; p = 0.69). The 2 groups received compar-
able immunosuppressive therapy, both in number and
type of treatment. Over 85% of patients received myco-
phenolate mofetil as maintenance immunosuppression in
addition to a calcineurin inhibitor in over 80% of patients.
Proteinuria and response to IVIG-MP treatment
Effect of treatment on proteinuria was analyzed and
compared for 41 patients. Sufficient data for statistical
analysis was missing for the remaining 28 patients. On
average IVIG-MP therapy was associated with a decrease
in proteinuria level the first year after administration.
Proteinuria initially increased in the 41 patients from 75
mg/mmol 1 year before therapy to 229 mg/mmol at time
of treatment (Fig. 5). In the year after treatment with
Fig. 2 a) Renal allograft function and response to therapy. The renal allograft function of the 69 patients one year before and one year after IVIG-
MP treatment (t0). *Calculated average decline in eGFR of 9.8 ml/min/1.73m
2 (p < 0.001) **Calculated average decline in eGFR of 6.3 ml/min/
1.73m2 (p < 0.001) ***change in slope of renal allograft function in the year before and after treatment (p < 0.001). b) Renal allograft function and
response to therapy of the responders. The renal allograft function of the 43 cases one year before and one year after IVIG-MP treatment (t 0).
*Calculated average decline in eGFR of 10.3 ml/min/1.73m2 (p < 0.001), **Calculated average decline in eGFR of 2.0 ml/min/1.73m2 (p < 0.001),
***change in renal allograft function (p < 0.001). c) Renal allograft function and response to therapy of non-responders. The renal allograft
function of the 26 patients one year before and one year after IVIG-MP treatment (t0). *Calculated average decline in eGFR of 9.1 ml/min/1.73m
2
(p < 0.001) **Calculated average decline in eGFR of 12.0 ml/min/1.73m2 (p < 0.001)
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IVIG-MP, proteinuria declined from 229mg/mmol to
190 mg/mmol. The calculated average decline in
proteinuria of 39 (1–79) mg/mmol the first year after
IVIG-MP treatment differed significantly (p < 0.001)
from the average increase in proteinuria of 154 (117–
192) mg/mmol in the year before treatment. Of the 41
treated patients, 25 were previously classified as
responders and 16 as non-responders. Although both
groups showed a significant response to treatment
(< 0.001), the non-responders showed a near stabilization
of proteinuria, whereas the responders had a decrease of
92 mg/mmol in the year after treatment (Fig. 5).
At time of treatment, 44% (n = 18) of patients were on
anti-proteinuric treatment with either an ACE inhibitor
and/or ARBs. Anti-proteinuric treatment was initiated in
15% of patients (n = 6) shortly after IVIG-MP treatment
and treatment was stopped for 1 patients. The remaining
patients had no additional form of anti-proteinuric
treatment (39%, n = 16).
Discussion
Chronic-active Antibody Mediated Rejection (c-aABMR)
is an important cause of renal allograft dysfunction over
time, often presenting as a continuous decline in allograft
function, either with or without proteinuria [7, 9–13].
Despite the growing awareness of the clinical significance,
there is no consensus on an effective therapeutic regimen
for patients with c-aABMR [28, 29]. Our data show that
IVIG-MP treatment of patients with c-aABMR has the
potential to significantly slow the progression of eGFR loss
within the first year after IVIG-MP administration.
There have been several studies published on the thera-
peutic approach of late or chronic ABMR. The majority of
these case-series report about their experience with known
desensitization protocols in various combinations (IVIG,
plasmapheresis, rituximab, tocilizumab) [16, 18, 19, 30–32].
Although the results are inconsistent, several studies have
shown a positive effect of therapy within the first year after
treatment which translated in improved allograft survival.
Other studies have shown that treatment (IVIG-rituximab)
for chronic ABMR does not seem to alter the progression
of decrease in allograft function [19].
Problematic in the afore mentioned studies are the
relatively small number of cases, the heterogeneity in
additional immune suppressive treatment and often the
lack of thorough statistical analysis of loss of allograft
function over time. Only recently the first randomized,
placebo-controlled trial for late ABMR was published
using bortezomib in the treatment arm. Unfortunately,
allograft function did not significantly differ between the
control and treatment arm [20].
In the current study, we analyzed a group of patients
with c-aABMR. Overall, there was a significant decrease
in eGFR loss when the decline in graft function in the year
before treatment was compared to the decrease in graft
function the year after treatment. However, it was clear
that the response to treatment was heterogeneous while in
about 2/3 of treated patients a significant treatment
response was achieved. The remaining patients had a rela-
tively unchanged loss of eGFR after treatment. The treat-
ment effect in the responders translated in improved graft
survival which was nearly double of that of the
non-responders. Of interest is that both allograft function
Fig. 3 Patterns of response to treatment with IVIG-MP for c-aABMR
related progressive loss of renal function. a) Typical example of a non-
responder; b) typical example of a responder with significant slowing
of the progressive decline in eGFR; c) typical example of a responder
with stabilization of the renal allograft function after treatment
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Fig. 4 Kaplan-Meier curves for renal graft survival censored for death for responders (n = 43) versus non-responders (n = 26) (log rank; p = 0.003)
Fig. 5 Proteinuria one year before and one year after IVIG-MP treatment (t0). Calculated average proteinuria of the whole group of treated
patients (n = 41; bold line) and both responders (n = 25; continuous line) and non-responders (n = 16; dotted line)
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and survival were similar in the non-responders and the
historic untreated group of c-aABMR patients.
This study has some obvious limitations. The study is
retrospective in nature allowing for unknown bias due
to a selection of patients with a for-cause biopsy. It also
excludes the possibility of a uniform schedule of, for
example, maintenance immunosuppression. It does
however, allow for a proper analyses of the decline in
allograft function. The multivariate analysis allows each
treated patient to be its own control comparing the
eGFR loss before and after treatment, strengthening our
finding that IVIG-MP seems to be beneficial in dimin-
ishing eGFR loss caused by c-aABMR. And although the
studied population is relatively small, it is to date, one of
the larger patient groups who have had a similar
treatment regimen after the diagnosis of c-aABMR. In
addition, significant response to treatment was unmis-
takable in some patients as shown in the figures.
Conclusion
In conclusion, immunosuppressive therapy with IVIG-MP
may significantly slow eGFR loss in a substantial propor-
tion of patients with c-aABMR leading to improved graft
survival. As c-aABMR is now recognized as a major cause
of long term renal allograft loss, the efficacy of IVIG-MP
treatment is an important and hopeful finding.
Additional file
Additional file 1: Table S1. Clinical and demographic characteristics of
cases and historic controls. (DOCX 16 kb)
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